Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Create alerts with multiple filters including highs/low, comparative values, and turning points. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Immunogen Inc (IMGN)

Immunogen Inc (IMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,189,643
  • Shares Outstanding, K 220,713
  • Annual Sales, $ 69,860 K
  • Annual Income, $ -139,300 K
  • 60-Month Beta 0.97
  • Price/Sales 17.22
  • Price/Cash Flow N/A
  • Price/Book 4.81
Trade IMGN with:

Options Overview Details

View History
  • Implied Volatility 70.51% ( +4.28%)
  • Historical Volatility 68.08%
  • IV Percentile 5%
  • IV Rank 7.27%
  • IV High 222.33% on 05/11/22
  • IV Low 58.61% on 05/27/22
  • Put/Call Vol Ratio 0.02
  • Today's Volume 618
  • Volume Avg (30-Day) 786
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 21,620
  • Open Int (30-Day) 18,864

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.27
  • Number of Estimates 8
  • High Estimate -0.23
  • Low Estimate -0.30
  • Prior Year -0.18
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.40 +19.77%
on 08/02/22
5.55 -5.05%
on 08/08/22
-0.19 (-3.48%)
since 07/08/22
3-Month
3.10 +70.27%
on 06/14/22
5.55 -5.05%
on 08/08/22
+1.28 (+32.08%)
since 05/09/22
52-Week
3.10 +70.27%
on 06/14/22
7.77 -32.18%
on 12/01/21
-0.41 (-7.22%)
since 08/09/21

Most Recent Stories

More News
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on July 29, 2022, the compensation committee of the...

IMGN : 5.27 (-2.23%)
ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates

ImmunoGen (IMGN) reports a wider-than-expected loss for second-quarter 2022. It also misses revenue estimates.

RHHBY : 41.5500 (+0.46%)
IMGN : 5.27 (-2.23%)
IONS : 44.26 (-3.17%)
VRCA : 3.25 (-4.97%)
ImmunoGen (IMGN) Q2 2022 Earnings Call Transcript

IMGN earnings call for the period ending June 30, 2022.

IMGN : 5.27 (-2.23%)
ImmunoGen (IMGN) Reports Q2 Loss, Lags Revenue Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of -9.09% and 16.74%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

IMGN : 5.27 (-2.23%)
ADXN : 1.4000 (+7.69%)
ImmunoGen Reports Recent Progress and Second Quarter 2022 Financial Results

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results...

IMGN : 5.27 (-2.23%)
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2022 Operating Results

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m....

IMGN : 5.27 (-2.23%)
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on June 30, 2022, the compensation committee of the...

IMGN : 5.27 (-2.23%)
ImmunoGen (IMGN) Enters New Collaboration to Boost ADC Pipeline

ImmunoGen (IMGN) inks a collaboration deal with privately-held Oxford BioTherapeutics to develop novel antibody-drug conjugates by complementing each other's proprietary technologies.

ALKS : 25.60 (-0.58%)
IMGN : 5.27 (-2.23%)
AGLE : 0.4125 (-3.40%)
SESN : 0.7057 (-3.33%)
ImmunoGen Announces Research Collaboration with Oxford BioTherapeutics to Develop Novel Antibody-Drug Conjugates

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced a multi-year collaboration to research novel, first-in-class...

IMGN : 5.27 (-2.23%)
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on May 31, 2022, the compensation committee of the...

IMGN : 5.27 (-2.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

ImmunoGen Inc is a development-stage biotechnology company focused on the development of targeted cancer therapeutics using its proprietary antibody-drug conjugate technology. ImmunoGen's ADC technology is used in three development-stage candidates in its own pipeline, Roche's marketed product, Kadcyla...

See More

Key Turning Points

3rd Resistance Point 5.74
2nd Resistance Point 5.59
1st Resistance Point 5.43
Last Price 5.27
1st Support Level 5.12
2nd Support Level 4.97
3rd Support Level 4.81

See More

52-Week High 7.77
Fibonacci 61.8% 5.98
Fibonacci 50% 5.43
Last Price 5.27
Fibonacci 38.2% 4.88
52-Week Low 3.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar